Indian Journal of Critical Care Medicine

Register      Login



Volume / Issue

Online First

Related articles

VOLUME 26 , ISSUE 3 ( March, 2022 ) > List of Articles

Original Article

Regulation of Calcium Homeostasis in Acute Kidney Injury: A Prospective Observational Study

Narinder Pal Singh, Vikrant Panwar, Neeru P Aggarwal, Satish K Chhabra, Anish K Gupta, Anirban Ganguli

Keywords : Acute kidney injury, Calcium homeostasis, Fibroblast growth factor-23, Parathyroid hormone, Vitamin D

Citation Information : Singh NP, Panwar V, Aggarwal NP, Chhabra SK, Gupta AK, Ganguli A. Regulation of Calcium Homeostasis in Acute Kidney Injury: A Prospective Observational Study. Indian J Crit Care Med 2022; 26 (3):302-306.

DOI: 10.5005/jp-journals-10071-24124

License: CC BY-NC 4.0

Published Online: 30-03-2022

Copyright Statement:  Copyright © 2022; The Author(s).


Background: Maintaining homeostasis is an integral part of all physiological processes both in health and disease including critically ill patients and may impact clinical outcomes. The present study was designed to assess prevalence of serum calcium, phosphate, vitamin-D3, FGF-23, and PTH levels abnormalities in AKI. Patients and methods: Single-center, prospective, observational study in a tertiary care hospital. Patients meeting KDIGO criteria for AKI were included. Paired blood samples were drawn from eligible patients—first sample within 24 hours of AKI diagnosis and second after 5 days or at time of hospital discharge, whichever was earlier for measuring serum calcium (albumin corrected), phosphate, PTH, 25(OH)Vit-D, and FGF-23 levels. Clinical outcomes analyzed included survival status, utilization of RRT, and hospital stay. Results: Of the 50 patients with AKI, about three-fourths were males. Mean age of the participants was 57.32 ± 11.47 years. Around half of patients had hypocalcemia and four-fifths had low serum phosphate. Nearly 82% had low 25(OH)Vit-D and 52% cases had high PTH level. Patients who underwent RRT had numerically higher but not significant serum calcium and PTH levels. FGF-23 levels (pg/mL) were significantly higher in patients on RRT (81.70 ± 17.30 vs non-RRT, 72.43 ± 20.27, p = 0.049), nonsurvivors (87.96 ± 18.82 vs survivors 57.11 ± 15.19, p = 0.045), and those hospitalized for time of stay above median (109.67 ± 26.97 vs below median 70.27 ± 20.43, p = 0.046). Among all the bone and mineral parameters analyzed high FGF23 levels were consistently linked with poor clinical outcomes in AKI. Conclusion: The present study found high prevalence of calcium and phosphate disorders in AKI with dysregulated phosphate homeostasis as evidenced from elevated FGF-23 levels linked with morbidity and mortality in AKI.

  1. Rewa O, Bagshaw SM. Acute kidney injury-epidemiology, outcomes and economics. Nat Rev Nephrol 2014;10(4):193–207. DOI: 10.1038/nrneph.2013.282.
  2. Ronco C, Kellum JA, Bellomo R. Potential interventions in sepsis related acute kidney injury. Clin J Am Soc Nephrol 2008;3(2):531–544. DOI: 10.2215/CJN.03830907.
  3. Adekola OO, Soriyan OO, Meka I. The incidence of electrolyte and acid-base abnormalities in critically ill patients using point of care testing (i-STAT portable analyser). Nig Q J Hosp Med 2012;22(2): 103–108. PMID: 23175907.
  4. Leaf DE, Wolf M, Waikar SS, Chase H, Christov M, Cremers S, et al. FGF-23 levels in patients with AKI and risk of adverse outcomes. Clin J Am Soc Nephrol 2012;7(8):1217–1223. DOI: 10.2215/CJN.00550112.
  5. Christov M, Waikar SS, Pereira RC, Havasi A, Leaf DE, Goltzman D, et al. Plasma FGF23 levels increase rapidly after acute kidney injury. Kidney Int 2013;84(4):776–785. DOI: 10.1038/ki.2013.150.
  6. Kellum JA, Lameire N, Aspelin P, Barsoum RS, Burdmann EA, Goldstein SL, et al. Kidney Disease: Improving Global Outcomes (KDIGO) Acute Kidney Injury Work Group. KDIGO clinical practice guideline for acute kidney injury. Kidney Int Suppl 2012;2(1):1–138. DOI: 10.1038/kisup.2012.7.
  7. Khatri M. Acute kidney injury is associated with increased hospital mortality after stroke. J Stroke Cerebrovasc Dis 2014;23(1):25–30. DOI: 10.1016/j.jstrokecerebrovasdis.2012.06.005.
  8. Mohamed W, Bhattacharya P, Shankar L, Chaturvedi S, Madhavan R. Which comorbidities and complications predict ischemic stroke recovery and length of stay? Neurologist 2015;20(2):27–32. DOI: 10.1097/NRL.0000000000000040.
  9. Saeed F, Adil MM, Khursheed F, Daimee UA, Branch LA Jr, Vidal GA, et al. Acute renal failure is associated with higher death and disability in patients with acute ischemic stroke: analysis of nationwide inpatient sample. Stroke 2014;45(5):1478–1480. DOI: 10.1161/STROKEAHA.114.004672.
  10. Saeed F, Adil MM, Piracha BH, Qureshi AI. Acute renal failure worsens in-hospital outcomes in patients with intra cerebral hemorrhage. J Stroke Cerebrovasc Dis 2015;24(4):789–794. DOI: 10.1016/j.jstrokecerebrovasdis.2014.11.012.
  11. Nadkarni GN, Patel AA, Konstantinidis I, Mahajan A, Agarwal SK, Kamat S, et al. Dialysis requiring acute kidney injury in acute cerebrovascular accident hospitalizations. Stroke 2015;46(11): 3226–3231. DOI: 10.1161/STROKEAHA.115.010985.
  12. Garg AX, Parikh CR. Yin and Yang: acute kidney injury and chronic kidney disease. J Am Soc Nephrol 2009;20(1):8–10. DOI: 10.1681/ASN.2008111197.
  13. Di Giuseppe R, Buijsse B, Hirche F, Wirth J, Arregui M, Westphal S, et al. Plasma fibroblast growth factor 23, parathyroid hormone, 25-hydroxyvitamin D3, and risk of heart failure: a prospective, case-cohort study. J Clin Endocrinol Metab 2014;99(3):947–955. DOI: 10.1210/jc.2013-2963.
  14. Ix JH, Katz R, Kestenbaum BR, de Boer IH, Chonchol M, Mukamal KJ, et al. Fibroblast growth factor-23 and death, heart failure, and cardiovascular events in community-living individuals: CHS (Cardiovascular Health Study). J Am Coll Cardiol 2012;60(3):200–207. DOI: 10.1016/j.jacc.2012.03.040.
  15. Scialla JJ, Xie H, Rahman M, Anderson AH, Isakova T, Ojo A, et al. Fibroblast growth factor-23 and cardiovascular events in CKD. J Am Soc Nephrol 2014;25(2):349–360. DOI: 10.1681/ASN.2013 050465.
  16. Isakova T, Xie H, Yang W, Xie D, Anderson AH, Scialla J, et al. Fibroblast growth factor 23 and risks of mortality and end-stage renal disease in patients with chronic kidney disease. Journal of the American Medical Association 2011;305(23):2432–2439. DOI: 10.1001/jama.2011.826.
  17. Leaf DE, Wolf M, Stern L. Elevated FGF-23 in a patient with rhabdomyolysis-induced acute kidney injury. Nephrol Dial Transplant 2010;25(4):1335–1337. DOI: 10.1093/ndt/gfp682.
  18. Zhang M, Hsu R, Hsu CY, Kordesch K, Nicasio E, Cortez A, et al. FGF-23 and PTH levels in patients with acute kidney injury: a cross-sectional case series study. Ann Intensive Care 2011;1(1):21. DOI: 10.1186/2110-5820-1-21.
  19. Bacchetta J, Sea JL, Chun RF, Lisse TS, Wesseling-Perry K, Gales B, et al. FGF23 inhibits extra-renal synthesis of 1,25-dihydroxyvitamin D in human monocytes. J Bone Miner Res 2013;28(1):46–55. DOI: 10.1002/jbmr.1740.
  20. Vijayan A, Li T, Dusso A, Jain S, Coyne DW. Relationship of 1,25-dihydroxy vitamin D levels to clinical outcomes in critically ill patients with acute kidney injury. J Nephrol Ther 2015;5(1):190. DOI: 10.4172/2161-0959.1000190.
  21. Leaf DE, Waikar SS, Wolf M, Cremers S, Bhan I, Stern L. Dysregulated mineral metabolism in patients with acute kidney injury and risk of adverse outcomes. Clin Endocrinol (Oxf) 2013;79(4):491–498. DOI: 10.1111/cen.12172.
  22. Zeid MM, Deghady AA, Elsaygh HK, El Shaer HS, Gawish RIA. Association of fibroblast growth factor 23, parathyroid hormone, and vitamin D with acute kidney injury. Egypt J Obes Diabetes Endocrinol 2016;2(2):88–94. DOI: 10.4103/2356-8062.197589.
PDF Share
PDF Share

© Jaypee Brothers Medical Publishers (P) LTD.